


In conclusion, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and mental disorders. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.


Summary of the Invention

~~In a first aspect, the~~The present ~~invention~~disclosure provides compounds of Formula (Ic)



wherein A, L, X, m, n, and R²⁰ to R²³ are as defined herein.

In one aspect, the present disclosure provides a compound of formula (Ic)



or a pharmaceutically acceptable salt thereof, wherein:

L is selected from -CR¹R²-(CH₂)_p-, -(CH₂)_p-CR¹R²-, -OCR³R⁴-, -CR³R⁴O-
and a covalent bond;


m is 0, n is 0 or 1 and X is CR²⁴; or

m is 1, n is 1 or 2 and X is CR²⁴ or N;

p is 0, 1 or 2;

R¹ is selected from halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl-, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy-C₁₋₆-alkyl-,

- 4a -



cyano, and a group _____; and R² is selected from hydrogen, halogen, and hydroxy; or

R¹ and R², taken together with the carbon atom to which they are attached, form a C₃₋₁₂-cycloalkyl or a C₂₋₉-heterocyclyl;


5 R³ is selected from C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₁₂-cycloalkyl, and C₆₋₁₄-aryl; and R⁴ is hydrogen; or

R³ and R⁴, taken together with the carbon atom to which they are attached, form a C₃₋₁₂-cycloalkyl or a C₂₋₉-heterocyclyl;


R²⁰ is hydrogen or C₁₋₆-alkyl;

10 R²¹, R²², and R²³ are independently selected from hydrogen, halogen, cyano, hydroxy, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, amino-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, (halo-C₁₋₆-alkyl)-hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl-, C₁₋₆-alkoxycarbonyl-NH-C₁₋₆-alkoxy-, C₁₋₆-alkoxycarbonyl-NH-(C₁₋₆-alkoxy)₂-C₁₋₆-alkyl-C(O)-NH-C₁₋₆-alkoxy-, C₁₋₆-alkoxycarbonyl-NH-C₁₋₆-alkoxy-C₁₋₆-alkyl-C(O)-NH-C₁₋₆-alkoxy-, SF₅, (C₁₋₆-

15 alkyl)₃Si-O-C₁₋₆-alkyl-, a group _____, and a group



alkyl)₃Si-O-C₁₋₆-alkyl-, a group _____, and a group



R²⁴ is selected from hydrogen, halogen, hydroxy, halo-C₁₋₆-alkyl, and C₁₋₆-alkyl;

20 R²⁵ and R²⁶ are independently selected from hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl-SO₂-, and C₃₋₁₂-cycloalkyl;

R²⁷ and R²⁸ are independently selected from hydrogen, halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, halogen, hydroxy, C₁₋₆-alkylsulfonyl, carbamoyl, cyano, cycloalkyl-C₁₋₆-alkoxy-, C₁₋₆-alkyl-NH-C(O)-, and cycloalkyl;

25

A, and B are independently selected from C₆₋₁₄-aryl, C₁₋₁₃-heteroaryl, C₃₋₁₂-cycloalkyl, and C₂₋₉-heterocyclcyl;

C¹ is C₃₋₁₂-cycloalkyl or C₂₋₉-heterocyclcyl;


C² is C₆₋₁₄-aryl;

5 L² is selected from a covalent bond, -O-, -CH₂O-, -CH₂OCH₂-, and -CH₂-;


L³ is selected from a covalent bond, -O-, -CH₂O-, -OCH₂-, -CH₂OCH₂-, and -CH₂-; and

L^{3a} is selected from a covalent bond, -CH₂O-, -OCH₂-, -CH₂OCH₂-, and -CH₂-.

In a further aspect, the present invention disclosure provides a process of
10 manufacturing the compounds of formula (Ic) as described herein, comprising:
reacting 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (1),




with a heterocyclic amine **2a**, wherein A, L, X, m, n, and R²⁰ to R²³ are as defined herein




15 in the presence of a base and a urea forming reagent,
to form said compounds of formula (Ic).

In a further aspect, the present disclosure provides a process of manufacturing the
compounds of formula (Ic) as described herein, or a pharmaceutically acceptable salt
20 thereof, comprising:

reacting 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (1),



with a heterocyclic amine **2a**, wherein A, L, X, m, n, and R²⁰ to R²³ are as described herein



in the presence of a base and a urea forming reagent,

to form said compound of formula (Ic).

- 5 ~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (Ic) as described herein, when manufactured according to the processes described herein.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (Ic) as described herein, for use as therapeutically active substance.

- 10 In a further aspect, the present disclosure provides a compound of formula (Ic) as described herein, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a pharmaceutical composition comprising a compound of formula (Ic) as described herein and a therapeutically inert carrier.

5 ~~In a further aspect, the~~In a further aspect, the present disclosure provides a pharmaceutical composition comprising a compound of formula (Ic) as described herein, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (Ic) as described herein for inhibiting monoacylglycerol lipase (MAGL) in a mammal.

10 ~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (Ic) as described herein for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (Ic) as described herein for the treatment or prophylaxis of multiple sclerosis,
15 Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula
20 (Ic) as described herein for use in a method of inhibiting monoacylglycerol lipase in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (Ic) as described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

25 ~~In a further aspect, the~~In a further aspect, the present disclosure provides a compound of formula (Ic) as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (Ic) as described herein, for use in the treatment or prophylaxis of multiple sclerosis,

Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular

- 5 carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (Ic) as described herein for the preparation of a medicament for inhibiting monoacylglycerol lipase in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (Ic) as described herein for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

- 5 In a further aspect, the present disclosure provides use of a compound of formula (Ic) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (Ic) as described herein for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity
15 associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a method for inhibiting monoacylglycerol lipase in a mammal, which method comprises administering an effective amount of a compound of formula (Ic) as described herein to the mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a method for the treatment
20 or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (Ic) as described herein to the mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease,
25 amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises administering an effective amount of a compound of formula (Ic) as described herein to
30 the mammal.


Detailed Description of the Invention

Definitions

Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be
5 understood to be applicable to any other aspect, embodiment or example described herein,

CLAIMS

1. A compound of formula (Ic)



or a pharmaceutically acceptable salt thereof, wherein:


5 L is selected from $-\text{CR}^1\text{R}^2-(\text{CH}_2)_p-$, $-(\text{CH}_2)_p-\text{CR}^1\text{R}^2-$, $-\text{OCR}^3\text{R}^4-$, $-\text{CR}^3\text{R}^4\text{O}-$ and a covalent bond;

m is 0, n is 0 or 1 and X is CR^{24} ; or

m is 1, n is 1 or 2 and X is CR^{24} or N;

p is 0, 1 or 2;

10 R¹ is selected from halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl-, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy-C₁₋₆-alkyl-,

cyano, and a group ; and R² is selected from hydrogen, halogen, and hydroxy; or

15 R¹ and R², taken together with the carbon atom to which they are attached, form a C₃₋₁₂-cycloalkyl or a C₂₋₉-heterocyclyl;


R³ is selected from C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₁₂-cycloalkyl, and C₆₋₁₄-aryl; and R⁴ is hydrogen; or


R³ and R⁴, taken together with the carbon atom to which they are attached, form a C₃₋₁₂-cycloalkyl or a C₂₋₉-heterocyclyl;

20 R²⁰ is hydrogen or C₁₋₆-alkyl;

25 R²¹, R²², and R²³ are independently selected from hydrogen, halogen, cyano, hydroxy, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, amino-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, (halo-C₁₋₆-alkyl)-hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl-, C₁₋₆-alkoxycarbonyl-NH-C₁₋₆-alkoxy-, C₁₋₆-alkoxycarbonyl-NH-(C₁₋₆-alkoxy)₂-C₁₋₆-alkyl-C(O)-NH-C₁₋₆-alkoxy-, C₁₋₆-

alkoxycarbonyl-NH-C₁₋₆-alkoxy-C₁₋₆-alkyl-C(O)-NH-C₁₋₆-alkoxy-, SF₅, (C₁₋₆-

alkyl)₃Si-O-C₁₋₆-alkyl-, a group , and a group



R²⁴ is selected from hydrogen, halogen, hydroxy, halo-C₁₋₆-alkyl, and C₁₋₆-alkyl;

5 R²⁵ and R²⁶ are independently selected from hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl-SO₂-, and C₃₋₁₂-cycloalkyl;

10 R²⁷ and R²⁸ are independently selected from hydrogen, halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, halogen, hydroxy, C₁₋₆-alkylsulfonyl, carbamoyl, cyano, cycloalkyl-C₁₋₆-alkoxy-, C₁₋₆-alkyl-NH-C(O)-, and cycloalkyl;

A, and B are independently selected from C₆₋₁₄-aryl, C₁₋₁₃-heteroaryl, C₃₋₁₂-cycloalkyl, and C₂₋₉-heterocyclyl;

C¹ is C₃₋₁₂-cycloalkyl or C₂₋₉-heterocyclyl;


15 C² is C₆₋₁₄-aryl;

L² is selected from a covalent bond, -O-, -CH₂O-, -CH₂OCH₂-, and -CH₂-;

L³ is selected from a covalent bond, -O-, -CH₂O-, -OCH₂-, -CH₂OCH₂-, and -CH₂-; and


L^{3a} is selected from a covalent bond, -CH₂O-, -OCH₂-, -CH₂OCH₂-, and -CH₂-.

20 2. The compound of formula (Ic) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (Ic) is a compound of formula (Id):




wherein A, L, X, m, n, and R²⁰-R²³ are as defined in claim 1.

3. The compound of formula (Ic) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (Ic) is a compound of formula (Ie):



wherein A, L, X, m, n, and R²⁰-R²³ are as defined in claim 1.


4. The compound of formula (Ic) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:
m is 0, n is 0 or 1 and X is CR²⁴; or
m is 1, n is 1 and X is CR²⁴ or N.
5. The compound of formula (Ic) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein p is 0 or 1.
6. The compound of formula (Ic) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein p is 0.
7. The compound of formula (Ic) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein:
R¹ is selected from halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl-, halo-C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy-C₁₋₆-alkyl-, cyano,



and a group ; and R² is selected from hydrogen, halogen, and hydroxy; or


R¹ and R², taken together with the carbon atom to which they are attached, form a C₃₋₁₂-cycloalkyl.

8. The compound of formula (Ic) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from halogen, C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl-, halo- C_{1-6} -alkoxy, and a group



; and R^2 is hydrogen or halogen.

- 5 9. The compound of formula (Ic) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from 2-methoxyethyl, methyl, 2,2,2-trifluoroethoxy, fluoro, 2-hydroxyethyl, and a group



; and R^2 is hydrogen or fluoro.



- 10 10. The compound of formula (Ic) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{1-6} -alkyl or halo- C_{1-6} -alkyl; and R^4 is hydrogen.

11. The compound of formula (Ic) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{1-6} -alkyl; and R^4 is hydrogen.


- 15 12. The compound of formula (Ic) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^3 is methyl; and R^4 is hydrogen.

13. The compound of formula (Ic) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^{20} is hydrogen.


- 20 14. The compound of formula (Ic) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R^{21} is selected from hydrogen, halogen, hydroxy, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, (halo- C_{1-6} -alkyl)-hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl- C_{1-6} -alkyl-, C_{1-6} -alkoxycarbonyl-NH- C_{1-6} -alkoxy-, SF_5 , $(C_{1-6}\text{-alkyl})_3Si-O-C_{1-6}\text{-alkyl-}$, a

group , and a group , wherein R²⁷, R²⁸, C¹, C², L³, and L^{3a} are as defined herein.

15. The compound of formula (Ic) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R²¹ is selected from halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, SF₅, C₆₋₁₄-aryl, and a group

, wherein R²⁷, R²⁸, C¹, and L³ are as defined herein.

16. The compound of formula (Ic) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R²¹ is selected from fluoro, chloro, bromo, methyl, methoxy, *tert*-butyl, propyl, trifluoromethoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, SF₅, phenyl,

and a group , wherein R²⁷, R²⁸, C¹, and L³ are as defined herein.

17. The compound of formula (Ic) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R²² is selected from hydrogen, halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, and cyano.


18. The compound of formula (Ic) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R²² is selected from hydrogen, halogen, C₁₋₆-alkoxy and halo-C₁₋₆-alkoxy.

19. The compound of formula (Ic) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R²² is selected from hydrogen, fluoro, chloro, methoxy, methyl, and trifluoromethyl.

20. The compound of formula (Ic) according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein R^{23} is hydrogen or halogen.
21. The compound of formula (Ic) according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein R^{23} is hydrogen or fluoro.
- 5 22. The compound of formula (Ic) according to any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein R^{24} is hydrogen.
23. The compound of formula (Ic) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R^{25} is selected from hydrogen, halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, halo- C_{1-6} -alkoxy, C_{1-6} -alkyl-SO₂-,
10 and C_{3-12} -cycloalkyl.
24. The compound of formula (Ic) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R^{25} is selected from hydrogen, halogen, C_{1-6} -alkoxy, and C_{3-12} -cycloalkyl.
25. The compound of formula (Ic) according to any one of claims 1 to 22, or a
15 pharmaceutically acceptable salt thereof, wherein R^{25} is selected from hydrogen, methoxy, fluoro, and cyclopropyl.
26. The compound of formula (Ic) according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R^{26} is selected from hydrogen, C_{1-6} -alkyl, and C_{1-6} -alkoxy.
- 20 27. The compound of formula (Ic) according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R^{26} is hydrogen or C_{1-6} -alkoxy.
28. The compound of formula (Ic) according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R^{26} is hydrogen or methoxy.
29. The compound of formula (Ic) according to any one of claims 1 to 28, or a
25 pharmaceutically acceptable salt thereof, wherein R^{27} is selected from hydrogen, halo- C_{1-6} -alkoxy, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, C_{1-6} -alkyl-NH-C(O)-, and halogen.

30. The compound of formula (Ic) according to any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R^{27} is selected from methyl, trifluoromethoxy, trifluoromethyl, 2,2,2-trifluoro-1-methyl-ethoxy, 2,2,2-trifluoro-1,1-dimethyl-ethoxy, 2,2,2-trifluoroethoxy, fluoro, and chloro.
- 5 31. The compound of formula (Ic) according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein R^{28} is selected from hydrogen, C_{1-6} -alkyl, and halogen.
32. The compound of formula (Ic) according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein R^{28} is selected from hydrogen,
10 methyl, fluoro, and chloro.
33. The compound of formula (Ic) according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein A is C_{6-14} -aryl or C_{1-13} -heteroaryl.
34. The compound of formula (Ic) according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein A is selected from phenyl, indol-3-
15 yl, 2-pyridyl, and 3-pyridyl.
35. The compound of formula (Ic) according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein B is C_{6-14} -aryl or C_{1-13} -heteroaryl.
36. The compound of formula (Ic) according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein B is phenyl or 1,2,4-oxadiazol-5-
20 yl.
37. The compound of formula (Ic) according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein C^1 is selected from azetidin-1-yl, pyrrolidin-1-yl, cyclopropyl, and oxetan-3-yl.
38. The compound of formula (Ic) according to any one of claims 1 to 37, or a
25 pharmaceutically acceptable salt thereof, wherein C^2 is phenyl.

39. The compound of formula (Ic) according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein L is selected from $-\text{CR}^1\text{R}^2-$, $(\text{CH}_2)_p-$, $-\text{OCR}^3\text{R}^4-$, $-\text{CR}^3\text{R}^4\text{O}-$ and a covalent bond; wherein R^1 to R^4 and p are as defined herein.
- 5 40. The compound of formula (Ic) according to any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, wherein L^2 is selected from a covalent bond, $-\text{O}-$, and $-\text{CH}_2-$.
41. The compound of formula (Ic) according to any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, wherein L^2 is a covalent bond.
- 10 42. The compound of formula (Ic) according to any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein L^3 is selected from a covalent bond, $-\text{CH}_2\text{O}-$, and $-\text{CH}_2-$.
43. The compound of formula (Ic) according to any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein L^3 is a covalent bond or $-\text{CH}_2-$.
- 15 44. The compound of formula (Ic) according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein L^{3a} is a covalent bond or $-\text{CH}_2-$.
45. The compound of formula (Ic) according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein L^{3a} is a covalent bond.
46. The compound of formula (Ic) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:
20 m is 0, n is 0 or 1 and X is CR^{24} ; or
m is 1, n is 1 and X is CR^{24} or N;
L is selected from $-\text{CR}^1\text{R}^2-(\text{CH}_2)_p-$, $-\text{OCHR}^3-$, $-\text{CHR}^3\text{O}-$ and a covalent bond;
p is 0 or 1;
25 R^1 is selected from halogen, C_{1-6} -alkoxy, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl-, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy- C_{1-6} -alkyl-,




cyano, and a group ; and R² is selected from hydrogen, halogen, and hydroxy; or

R¹ and R², taken together with the carbon atom to which they are attached, form a C₃₋₁₂-cycloalkyl;


5 R³ is C₁₋₆-alkyl or halo-C₁₋₆-alkyl;

R²⁰ is hydrogen or C₁₋₆-alkyl;

R²¹ is selected from hydrogen, halogen, hydroxy, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, (halo-C₁₋₆-alkyl)-hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl-, C₁₋₆-alkoxycarbonyl-NH-C₁₋₆-alkoxy-,



10 SF₅, (C₁₋₆-alkyl)₃Si-O-C₁₋₆-alkyl-, a group , and a group



R²² is selected from hydrogen, halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, and cyano;

R²³ is hydrogen or halogen;

15 R²⁴ is selected from hydrogen, halogen, hydroxy, and C₁₋₆-alkyl;

R²⁵ is selected from hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl-SO₂-, and C₃₋₁₂-cycloalkyl;

R²⁶ is selected from hydrogen, C₁₋₆-alkyl, and C₁₋₆-alkoxy;

R²⁷ is selected from hydrogen, halogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, halogen, hydroxy, C₁₋₆-alkylsulfonyl, carbamoyl, cyano, cycloalkyl-C₁₋₆-alkoxy-, and cycloalkyl;

20 R²⁸ is selected from hydrogen, C₁₋₆-alkyl, and halogen;

A is C₆₋₁₄-aryl or C₁₋₁₃-heteroaryl;

B is C₆₋₁₄-aryl or C₁₋₁₃-heteroaryl;

25 C¹ is C₃₋₁₂-cycloalkyl or C₂₋₉-heterocyclyl;

C^2 is C_{6-14} -aryl;

L^2 is selected from a covalent bond, $-O-$, and $-CH_2-$;

L^3 is selected from a covalent bond, $-CH_2O-$, and $-CH_2-$; and

L^{3a} is a covalent bond or $-CH_2-$.


- 5 47. The compound of formula (Ic) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:

m is 0, n is 0 or 1 and X is CH; or

m is 1, n is 1 and X is CH or N;

L is selected from $-CR^1R^2-$, $-OCHR^3-$, $-CHR^3O-$ and a covalent bond;

10 R^1 is selected from halogen, C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -




R^2 is hydrogen or halogen;

R^3 is C_{1-6} -alkyl;

R^{20} is hydrogen;

15 R^{21} is selected from halogen, C_{1-6} -alkoxy, halo- C_{1-6} -alkoxy, C_{1-6} -alkyl, halo- C_{1-6} -



R^{22} is selected from hydrogen, halogen, C_{1-6} -alkoxy and halo- C_{1-6} -alkoxy;

R^{23} is hydrogen or halogen;

R^{25} is selected from hydrogen, halogen, C_{1-6} -alkoxy, and C_{3-12} -cycloalkyl;

20 R^{26} is hydrogen or C_{1-6} -alkoxy;

R^{27} is selected from hydrogen, halo- C_{1-6} -alkoxy, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, and halogen;

R^{28} is selected from hydrogen, C_{1-6} -alkyl, and halogen;

A is C_{6-14} -aryl or C_{1-13} -heteroaryl;

25 B is C_{6-14} -aryl or C_{1-13} -heteroaryl;

C^1 is C_{3-12} -cycloalkyl or C_{2-9} -heterocyclyl; and

L^3 is a covalent bond or $-\text{CH}_2-$.


48. The compound of formula (Ic) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:

m is 0, n is 0 or 1 and X is CH; or

5 m is 1, n is 1 and X is CH or N;

L is selected from $-\text{CR}^1\text{R}^2-$, $-\text{OCHR}^3-$, $-\text{CHR}^3\text{O}-$ and a covalent bond;

R^1 is selected from 2-methoxyethyl, methyl, 2,2,2-trifluoroethoxy, fluoro, 2-




R^2 is hydrogen or fluoro;

10 R^3 is methyl;

R^{20} is hydrogen;

R^{21} is selected from fluoro, chloro, bromo, methyl, methoxy, *tert*-butyl, propyl, trifluoromethoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, trifluoromethyl, 2,2,2-



15 R^{22} is selected from hydrogen, fluoro, chloro, methoxy, methyl, and trifluoromethyl;

R^{23} is hydrogen or fluoro;

R^{25} is selected from hydrogen, methoxy, fluoro, and cyclopropyl;

R^{26} is hydrogen or methoxy;

20 R^{27} is selected from methyl, trifluoromethoxy, trifluoromethyl, 2,2,2-trifluoro-1-methyl-ethoxy, 2,2,2-trifluoro-1,1-dimethyl-ethoxy, 2,2,2-trifluoroethoxy, fluoro, and chloro;

R^{28} is selected from hydrogen, methyl, fluoro, and chloro;

A is selected from phenyl, indol-3-yl, 2-pyridyl, and 3-pyridyl;

25 B is phenyl or 1,2,4-oxadiazol-5-yl;

C¹ is selected from azetidin-1-yl, pyrrolidin-1-yl, cyclopropyl, and oxetan-3-yl;
and

L³ is a covalent bond or –CH₂–.

49. The compound of formula (I) according to any one of claims 1 to 48, or a
pharmaceutically acceptable salt thereof, selected from: ~~the compounds disclosed in~~
~~Table 1 and Table 3~~

rac-(4aR,8aS)-6-(4-Benzhydrylpiperidine-1-carbonyl)-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;

rac-(4aR,8aS)-6-(4-(5-Chloro-1-(cyclopropylmethyl)-1H-indol-3-yl)piperidine-1-
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(4-(5-Chloro-1-methyl-1H-indol-3-yl)piperidine-1-
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(4-(9H-Fluoren-9-yl)piperidine-1-carbonyl)hexahydro-2H-
pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)-cis-6-[4-(6-Fluoro-1H-indol-3-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(4-(1-(4-Fluorophenyl)-3-methoxypropyl)piperidine-1-
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-[4-(6-Fluoro-1H-indol-3-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-(4-((4-Fluorophenyl)(methoxy)methyl)piperidine-1-
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-(4-(5-Fluorobenzo[d]isoxazol-3-yl)piperidine-1-
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

cis-6-(4-((4-Chlorophenyl)(phenyl)methyl)piperazine-1-carbonyl)hexahydro-2H-
pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(+)-cis-6-(4-(bis(4-Fluorophenyl)methyl)piperazine-1-carbonyl)hexahydro-2H-
pyrido[4,3-b][1,4]oxazin-3(4H)-one;

rac-(4aR,8aS)-6-[4-[bis(4-Fluorophenyl)methyl]piperazine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (-)-cis-6-(4-(bis(4-Fluorophenyl)methyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-(4aR,8aS)-6-(4-(5-Chloro-1H-indol-3-yl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 rac-(4aR,8aS)-6-(4-(1-Phenylethyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-(4aR,8aS)-6-(4-(1-Methyl-1H-indazol-5-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-(4aR,8aS)-6-[4-[(4-Fluorophenyl)-phenylmethyl]piperazine-1-carbonyl]-
- 10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one ;
- (E/Z)-3-[4-[rac-(4aS,8aR)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperazin-1-yl]-2-phenylprop-2-enenitrile;
- (+)- or (-)-cis-6-(4-(5-Chloro-1-cyclopropyl-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 rac-(4aR,8aS)-6-(4-(5-Chloro-1-(1-chloro-3-hydroxypropan-2-yl)-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-cis-6-(4-(bis(4-Fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)-or (-)-cis-6-(4-(5-Chloro-1-(oxetan-3-yl)-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (+)- or (-)-cis-6-(4-(5-Chloro-1-(oxetan-3-ylmethyl)-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+)- or (-)-cis-6-(4-(1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-5-chloro-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (+)- or (-)-cis-6-(4-(5-Chloro-1-(2-hydroxyethyl)-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-cis-6-(4-(1-(4-Fluorophenyl)-3-hydroxypropyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-(4aR,8aS)-6-(4-(1-(4-(Trifluoromethyl)phenyl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30

- rac-(4aR,8aS)-6-(4-(1-(2-Chloro-4-fluorophenoxy)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(4-(5-(Trifluoromethyl)pyridin-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
5 (4aR,8aS)-6-(4-(Difluoro(4-(trifluoromethyl)phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-(4aR,8aS)-6-(4-((R or S)-1-(4-Fluorophenyl)-3-hydroxypropyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(-)-(4aR,8aS)-6-(4-((S or R)-1-(4-Fluorophenyl)-3-hydroxypropyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
10 (+) or (-)-cis-6-(4-((S or R)-1-(2-Chloro-4-fluorophenoxy)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+) or (-)-cis-6-(4-((R or S)-1-(2-Chloro-4-fluorophenoxy)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
15 (+) or (-)-cis-6-(4-(5-Methoxypyridin-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+) or (-)-cis-6-(4-(Bis(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+) or (-)-cis-6-(4-((4-Chlorophenyl)difluoromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
20 (+) or (-)-cis-6-(4-(5-(Trifluoromethoxy)pyridin-2-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+) or (-)-cis-6-(4-((2-Chloro-4-fluorophenyl)difluoromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
25 (+) or (-)-cis-6-(4-(5-Ethylpyridin-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+) or (-)-cis-6-(4-(5-(1,1-Difluoroethyl)pyridin-2-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+) or (-)-cis-6-(4-(6-Chloro-1-methyl-1H-indazol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
30

- (4aR,8aS)-6-((3R or 3S)-4-(5-(1,1-Difluoroethyl)pyridin-2-yl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-((3S or 3R)-4-(5-(1,1-Difluoroethyl)pyridin-2-yl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-((4R or 4S)-4-(5-(1,1-Difluoroethyl)pyridin-2-yl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((R or S)-1-(4-(Trifluoromethyl)phenyl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-1-(4-(Trifluoromethyl)phenyl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 2-(4-Fluorophenyl)-2-(1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)acetonitrile;
- (4aR,8aS)-6-(4-(2,2,2-Trifluoro-1-phenylethyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(4-((4-Fluorophenyl)(2,2,2-trifluoroethoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-(1-(4-Fluorophenyl)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(4-(1-(4-(Trifluoromethyl)phenyl)cyclopropyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-(1-(2,4-Difluorophenyl)-2,2,2-trifluoroethyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(Bis(4-fluorophenyl)(hydroxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-(Fluorobis(4-fluorophenyl)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-(1-(4-Fluorophenyl)-2-(2,2,2-trifluoroethoxy)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30 (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(2,2,2-trifluoroethoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(4-((S or R)-(4-Fluorophenyl)(2,2,2-trifluoroethoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((R or S)-1-(4-Fluorophenyl)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-1-(4-Fluorophenyl)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-(2-Cyclopropylpyridin-4-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[(S or R)-(4-Fluorophenyl)-(3-methoxyphenyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(3-methoxyphenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(3-Methoxyphenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((R or S)-(3-Methoxyphenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(3-(2-Fluoroethoxy)phenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S)-(4-Fluorophenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(4-Fluorophenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[(S or R)-(4-Fluorophenyl)-(4-methylphenyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(R or S)-[4-(2-Fluoroethoxy)phenyl]-phenylmethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(4-((S or R)-(4-Fluorophenyl)(4-methoxyphenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(p-tolyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(3,4-Dimethoxyphenyl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(4-((R or S)-(3,4-Dimethoxyphenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(1-(2-Chloro-4-(trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(1-(2-Chloro-4-(trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-Phenyl(m-tolyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-[4-[(S or R)-[4-(2-Fluoroethoxy)phenyl]-phenylmethyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(4-((S or R)-((S)-3-Methylcyclohexa-2,4-dien-1-yl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(4-(1-(2-Chloro-4-fluorophenoxy)-2,2,2-trifluoroethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(bis(4-Fluorophenyl)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[1-[4-(Trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-[4-[(S or R)-Phenyl(p-tolyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(4-((R or S)-Phenyl(p-tolyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30 (4aR,8aS)-6-(3-Benzhydrylazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(4-((S or R)-(3,4-Dimethoxyphenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((R or S)-(3,4-Dimethoxyphenyl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(4-methoxyphenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[1-[4-(Trifluoromethyl)phenyl]ethoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(1-(2-Fluoro-4-(trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(3-(1-(4-(Trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[1-[4-(Trifluoromethyl)phenyl]ethoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 (4aR,8aS)-6-(4-((R or S)-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(3-((R or S)-1-(2-Fluoro-4-(trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-((S or R)-1-(2-Fluoro-4-(trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-((R or S)-1-(4-(Trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-((S or R)-1-(4-(Trifluoromethyl)phenoxy)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30 (4aR,8aS)-6-(4-((R or S)-(4-(2-Fluoroethoxy)phenyl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(4-(5-Methyl-6-(trifluoromethyl)pyridin-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((4-Fluorophenyl)(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-((S or R)-1-(4-(Trifluoromethyl)phenyl)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-((R or S)-1-(4-(Trifluoromethyl)phenyl)ethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-(S or R)-[(4-Fluorophenyl)-(2,2,2-trifluoroethoxy)methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(R or S)-[(4-Fluorophenyl)-(2,2,2-trifluoroethoxy)methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(4-(5,6,7,8-Tetrahydroquinolin-4-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((R or S)-(3-(2-Fluoroethoxy)phenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(4-(2-Fluoroethoxy)phenyl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-Bromophenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4'-Chloro-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2'-Chloro-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2',4'-Dichloro-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(1-(R or S)-(4-(Trifluoromethyl)phenyl)ethoxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(3-(1-(S or R)-(4-(Trifluoromethyl)phenyl)ethoxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-(S or R)-[1-(2-Chloro-4-fluoro-phenyl)ethoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[3-(R or S)-[1-(2-Chloro-4-fluoro-phenyl)ethoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(R or S)-(3,4-Dimethoxyphenyl)-(2-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(S or R)-(3,4-Dimethoxyphenyl)-(2-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 (4aR,8aS)-6-[3-[4-(Trifluoromethoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(2'-(Trifluoromethoxy)-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(4-Bromophenyl)-3-fluoroazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-Bromophenyl)-3-hydroxyazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-Bromophenyl)-3-methylazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(3-(2'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 4'-(1-((4aR,8aS)-3-Oxo-octahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-yl)-[1,1'-biphenyl]-2-carbonitrile;
- (4aR,8aS)-6-(3-(4-(3-Methoxyazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(Trifluoromethyl)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30

- 2-[4-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]phenyl]benzamide;
(4aR,8aS)-6-(3-(2-Chloro-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
5 (4aR,8aS)-6-(3-(4-Bromo-3-chlorophenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[3-[4-(4-Chloro-2-fluoro-phenyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[4-(2-Chloro-4-fluoro-phenyl)phenyl]azetidine-1-carbonyl]-
10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[(R or S)-(3,4-Dimethoxyphenyl)-(3-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[(S or R)-(3,4-dimethoxyphenyl)-(3-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
15 (4aR,8aS)-6-(3-(2'-Methyl-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-(4-(3-((1,1,1-Trifluoropropan-2-yl)oxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
20 (4aR,8aS)-6-(3-(3-Bromophenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-(4-(tert-Butyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[3-(4-Phenylphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-
25 hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[4-[2-(Difluoromethyl)phenyl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(3-(3'-Methyl-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
30 (4aR,8aS)-6-(3-(4'-Methyl-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(3-(6-Chloropyridin-3-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(Trifluoromethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(3-(4-(3-((1,1,1-Trifluoro-2-methylpropan-2-yl)oxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(1,1-Difluoroethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-[4-[(R or S)-(3,4-Dimethoxyphenyl)-(4-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(S or R)-(3,4-Dimethoxyphenyl)-(4-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(4-(3-Methylazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(4-(3,3-Dimethylpyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(Trifluoromethoxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(3-(6-(2,4-Dichlorophenyl)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2'-Chloro-4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3,3-Difluoroazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(4-(4-Bromophenyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(2,2,2-Trifluoroethoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30 2-[4-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]phenyl]-5-chloro-benzonitrile;

- (4aR,8aS)-6-[3-[4-[3-[(1S or 1R)-2,2,2-Trifluoro-1-methyl-ethoxy]azetidin-1-yl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[3-[4-[3-[(1R or 1S)-2,2,2-Trifluoro-1-methyl-ethoxy]azetidin-1-yl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(4-(2-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(3-(3-Bromophenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(2-Ethylpyrrolidin-1-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 2-[4-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]phenyl]-3-chloro-benzonitrile;
- (4aR,8aS)-6-(3-(4-(2-Cyclopropylpyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-(4-Bromophenyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(4-(2',4'-Dichloro-[1,1'-biphenyl]-4-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-Azabicyclo[3.1.0]hexan-3-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-(3-(Trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(2,2,2-Trifluoroethoxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4'-chloro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30

- (4aR,8aS)-6-(3-(6-(2-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[(R or S)-(3-methylsulfonylphenyl)-(3-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[4-[(S or R)-(3-methylsulfonylphenyl)-(3-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(R or S)-(3-methylsulfonylphenyl)-(4-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(S or R)-(3-methylsulfonylphenyl)-(4-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 (4aR,8aS)-6-(3-(4-(5-Azaspiro[2.4]heptan-5-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(Pentafluoro-l6-sulfaneyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(5-Chloropyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2-Fluoro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-(6-methoxypyridin-3-yl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 20 (4aR,8aS)-6-(3-(4-Bromophenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-Phenylazetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(4-Phenylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(2,2,2-Trifluoroethyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[1-(Trifluoromethyl)cyclopropyl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30

- (4aR,8aS)-6-[4-[(R or S)-(3-Methylsulfonylphenyl)-(2-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-[(S or R)-(3-Methylsulfonylphenyl)-(2-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[3-[4-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(5-(2,4-Dichlorophenyl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(3-(4-((R or S)-2-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-((S or R)-2-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-[3-[4-(1-Piperidyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(4-((R or S)-3-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-((S or R)-3-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-[3-[4-(3-hydroxy-3-methylazetidin-1-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Fluoro-3-methylazetidin-1-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-(3-(4-(3-Fluoroazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-Fluoro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-Methyl-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30

- (4aR,8aS)-6-(3-(3,5-Difluoro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2-Chloro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(3-(4-(Bicyclo[1.1.1]pentan-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(5-(2-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(3-(1-Benzyl-5-chloro-1H-indol-3-yl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2-Fluoro-4-(trifluoromethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(3-Chloro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-[3-(Cyclopropylmethoxy)azetidin-1-yl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5-(1-((4aR,8aS)-3-Oxo-octahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-yl)-2-(trifluoromethoxy)benzonitrile;
- 20 (4aR,8aS)-6-(3-(4-(1-(Hydroxymethyl)cyclopropyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(1-Methyl-1H-indazol-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-(4-(3-Fluoropyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(2-Methylazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[phenyl(pyridazin-3-yl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30

- (4aR,8aS)-6-[3-[4-(Trifluoromethoxy)phenyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(1-Methyl-1H-indazol-6-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-[3-(S or R)-[3-(Trifluoromethoxy)phenyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(R or S)-[3-(Trifluoromethoxy)phenyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 (4aR,8aS)-6-(3-(3-Chloro-4-hydroxyphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-Chloro-4-(3-methylazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(Oxetan-3-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 (4aR,8aS)-6-(3-(3-Chloro-4-(3,3-difluoroazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-(3-Methylazetidin-1-yl)-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[(3S or R)-3-(3-Bromophenyl)pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 20 (4aR,8aS)-6-[(3R or S)-3-(3-Bromophenyl)pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Azabicyclo[3.1.1]heptan-3-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-(2-Methyl-3-(4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3,3-Dimethyl-2,3-dihydrobenzofuran-6-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-Chloro-5-(2,2,2-trifluoroethoxy)phenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30

- Methyl 2-methyl-2-(4-(1-((4aR,8aS)-3-Oxo-octahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)azetidin-3-yl)phenyl)propanoate;
- (4aR,8aS)-6-(3-(3,5-Dichlorophenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(3-(4-(3-Methoxy-3-methylazetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- tert-Butyl (2-(3-((1-((4aR,8aS)-3-oxo-octahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)(phenyl)methyl)phenoxy)ethyl)carbamate;
- 10 (4aR,8aS)-6-((R or S)-3-(3-Chloro-5-(2,2,2-trifluoroethoxy)phenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-((S or R)-3-(3-Chloro-5-(2,2,2-trifluoroethoxy)phenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(tert-Butyl)-3-methoxyphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(1-Methyl-1H-indazol-5-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-Propylphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(Trifluoromethoxy)-3-(trifluoromethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-[3-[4-[1-(Trifluoromethyl)cyclopropyl]methoxy]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2,2,2-Trifluoro-1,1-dimethyl-ethyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-[3-(R or S)-[4-(2,2,2-Trifluoro-1-methyl-ethoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Fluoropropyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30 (4aR,8aS)-6-[3-(S or R)-[4-(2,2,2-Trifluoro-1-methyl-ethoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (4aR,8aS)-6-[3-(4-Cyclobutylphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(3-Methoxy-4-methyl-phenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-(4-((4-Fluorophenyl)((1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[[3-(2-Aminoethoxy)phenyl]-phenyl-methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 (4aR,8aS)-6-[3-[5-(2,4-Dichlorophenyl)-1,3,4-oxadiazol-2-yl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[3-Fluoro-4-(trifluoromethyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 tert-Butyl N-[2-[3-[2-[3-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]-phenyl-methyl]phenoxy]ethylamino]-3-oxo-propoxy]ethyl]carbamate;
- tert-Butyl N-[2-[2-[3-[2-[3-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]-phenyl-methyl]phenoxy]ethylamino]-3-oxo-propoxy]ethoxy]ethyl]carbamate;
- 20 (4aR,8aS)-6-[3-[1-(2,4-Dichlorophenyl)pyrazol-3-yl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(4-Propoxyphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(3,4-Pimethylphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 2-[4-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]phenyl]-N-ethyl-5-methyl-benzamide;
- (4aR,8aS)-6-[3-[4-(2,2-Dimethylpropyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30 (4aR,8aS)-6-[3-(4-tert-Butoxyphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (4aR,8aS)-6-[4-(5-Chloroindolin-1-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-(4-Chloroisindolin-2-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[4-(5'-Chlorospiro[cyclopropane-1,3'-indoline]-1'-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(4-Chloroisindolin-2-yl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[4-(5-Chloroisindolin-2-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 (4aS,8aS)-6-[4-[1-[2-[tert-Butyl(dimethyl)silyl]oxyethyl]-5-chloro-indol-3-yl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aS,8aS)-6-[4-[5-Chloro-1-(2-hydroxyethyl)indol-3-yl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 (4aR,8aS)-6-(3-(5-(3-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(5-((R or S)-3-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(3-(5-((S or R)-3-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[6-[3-(Trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[6-[3-(R or S)-(Trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-[3-[6-[3S- or 3R-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(4-Tetrahydropyran-3-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30 (4aR,8aS)-6-[3-[2-Methoxy-4-(2,2,2-trifluoroethyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (4aR,8aS)-6-(3-(4-(Neopentyloxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- rac-(4aR,8aS)-6-[4-(3-Methoxy-1-phenyl-propyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 rac-(4aR,8aS)-6-[4-[Phenyl(3-pyridyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- rac-(4aR,8aS)-6-[4-[(5-Methyl-1,2,4-oxadiazol-3-yl)-phenyl-methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- rac-(4aR,8aS)-6-[4-(5-Fluoro-1-methyl-indol-3-yl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 tert-Butyl 3-[5-chloro-3-[1-[rac-(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]indol-1-yl]azetidine-1-carboxylate;
- tert-Butyl 3-[5-chloro-3-[1-[rac-(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidyl]indol-1-yl]azetidine-1-carboxylate;
- 15 rac-(4aR,8aS)-6-[4-[1-(2-Chloro-4-fluoro-phenoxy)propyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- rac-(4aR,8aS)-6-[4-[(2-Chloro-4-fluoro-phenoxy)-cyclopropyl-methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 20 rac-(4aR,8aS)-6-[4-[(4-Fluorophenoxy)-phenyl-methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- rac-(4aR,8aS)-6-[4-[5-(Trifluoromethyl)-2-pyridyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 rac-(4aR,8aS)-6-[4-[Cyclopropylmethoxy-[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- rac-(4aR,8aS)-6-[4-[1-(4-Fluorophenyl)-2-hydroxy-ethyl]piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30 rac-(4aR,8aS)-6-[4-[1-(4-Fluorophenyl)-2-methoxy-ethyl]piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- [rac-\(4aR,8aS\)-6-\[4-\[1-\(3,4-Difluorophenyl\)-2-hydroxy-ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[1-\(3,4-Difluorophenyl\)-2-methoxy-ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 5 [rac-\(4aR,8aS\)-6-\[4-\[1-\(4,4-Difluoro-1-piperidyl\)cyclopropyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[1-\[4-\(Trifluoromethyl\)imidazol-1-yl\]ethyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[1-\[4-\(Trifluoromethyl\)pyrazol-1-yl\]cyclopropyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 10 [rac-\(4aR,8aS\)-6-\[4-\[\(4-tert-Butyl\)pyrazol-1-yl\]-\(4-fluorophenyl\)methyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[3-\[4-\(Trifluoromethyl\)phenyl\]oxetan-3-yl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 15 [rac-\(4aR,8aS\)-6-\[4-\[4-\(Trifluoromethyl\)benzoyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[1-\[4-\(Trifluoromethyl\)pyrazol-1-yl\]ethyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[\(4-Fluorophenyl\)-morpholino-methyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 20 [rac-\(4aR,8aS\)-6-\[4-\[\(4-tert-Butyl\)oxazol-2-yl\]-difluoro-methyl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[1-\(4-Chlorophenyl\)-2-hydroxy-ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 25 [rac-\(4aR,8aS\)-6-\[4-\[1-\(4-Chlorophenyl\)-2-methoxy-ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[2-Hydroxy-1-\[4-\(trifluoromethyl\)phenyl\]ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[2-Methoxy-1-\[4-\(trifluoromethyl\)phenyl\]ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 30

- [rac-\(4aR,8aS\)-6-\[4-\(1-Cyclohexyl-2-methoxy-ethyl\)piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\(1-Cyclohexyl-2-hydroxy-ethyl\)piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 5 [rac-\(4aR,8aS\)-6-\[4-\[1-\(4-Fluorophenyl\)cyclopropyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[2-\(4-Fluorophenyl\)cyclopropyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[1-\(4-Fluorophenyl\)cyclobutyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 10 [rac-\(4aR,8aS\)-6-\[4-\[Cyclopropyl-\(4-fluorophenyl\)methyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[Cyclohexyl-\(4-fluorophenyl\)methyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 15 [rac-\(4aR,8aS\)-6-\[4-\[\(4-Fluorophenyl\)-\(4-pyridyl\)methyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[2,2,2-Trifluoro-1-\(4-fluorophenyl\)ethyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[\(4-Fluorophenyl\)-oxazol-5-yl-methyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 20 [rac-\(4aR,8aS\)-6-\[4-\[bis\(4-Chlorophenyl\)methyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aS,8aS\)-6-\[4-\[5-Chloro-1-\(cyclopropylmethyl\)indol-3-yl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 25 [rac-\(4aS,8aS\)-6-\[4-\[5-Chloro-1-\(cyclopropylmethyl\)indol-3-yl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aR\)-6-\[4-\[5-Chloro-1-\(cyclopropylmethyl\)indol-3-yl\]piperidine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- [rac-\(4aR,8aS\)-6-\[4-\[\(4-Chlorophenyl\)-\(4-fluorophenyl\)methyl\]piperazine-1-carbonyl\]-4,4a,5,7,8,8a-hexahydropyrido\[4,3-b\]\[1,4\]oxazin-3-one;](#)
- 30

rac-(4aR,8aS)-6-(4-Benzhydrylpiperazine-1-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-[4-[4-(2,2,2-Trifluoroethyl)phenyl]piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-[4-[3-(2,2,2-Trifluoroethyl)phenyl]piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-[4-[4-Chloro-3-(trifluoromethyl)phenyl]piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-[4-[1-[4-(Trifluoromethyl)phenyl]ethyl]piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
rac-(4aR,8aS)-6-[3-[1-(2-Chloro-4-fluoro-phenoxy)ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and
rac-(4aR,8aS)-6-[3-[5-Chloro-1-(cyclopropylmethyl)indol-3-yl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.

50. The compound of formula (I) according to any one of claims 1 to 48, or a pharmaceutically acceptable salt thereof, selected from:
- rac-cis-6-(4-(5-Chloro-1-(cyclopropylmethyl)-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-cis-6-(4-(5-Chloro-1-methyl-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-cis-6-(4-(1-(4-Fluorophenyl)-3-methoxypropyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-cis-6-(4-((4-Chlorophenyl)(phenyl)methyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-cis-6-(4-(bis(4-Fluorophenyl)methyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or (-)-cis-6-(4-(5-Chloro-1-cyclopropyl-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-or (-)-cis-6-(4-(5-Chloro-1-(oxetan-3-yl)-1H-indol-3-yl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- rac-cis-6-(4-(1-(4-Fluorophenyl)-3-hydroxypropyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-(Difluoro(4-(trifluoromethyl)phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (+) or (-)-cis-6-(4-((R or S)-1-(2-chloro-4-fluorophenoxy)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+) or (-)-cis-6-(4-((4-Chlorophenyl)difluoromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (+) or (-)-cis-6-(4-((2-Chloro-4-fluorophenyl)difluoromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(4-((R or S)-1-(4-(Trifluoromethyl)phenyl)ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(4-Fluorophenyl)(2,2,2-trifluoroethoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-[4-[(S or R)-(4-Fluorophenyl)-(3-methoxyphenyl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahdropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(3-methoxyphenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(3-(2-Fluoroethoxy)phenyl)(phenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(4-((3-Cyclopropyl-1,2,4-oxadiazol-5-yl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((S or R)-(4-Fluorophenyl)(4-methoxyphenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(4-((S or R)-(3,4-Dimethoxyphenyl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(4-((R or S)-(4-Fluorophenyl)(4-methoxyphenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;


- (4aR,8aS)-6-(4-((S or R)-(4-(2-Fluoroethoxy)phenyl)(4-fluorophenyl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(Trifluoromethoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-(3-(2'-Trifluoromethoxy)-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(2'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(3-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(Trifluoromethyl)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-Bromo-3-chlorophenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-[3-[4-(4-Chloro-2-fluoro-phenyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2-Chloro-4-fluoro-phenyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 20 (4aR,8aS)-6-(3-(4-(3-((1,1,1-Trifluoropropan-2-yl)oxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(tert-Butyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-(4-(Trifluoromethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-((1,1,1-Trifluoro-2-methylpropan-2-yl)oxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30 (4aR,8aS)-6-(3-(4-(1,1-Difluoroethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

- (4aR,8aS)-6-(3-(4-(3,3-Dimethylpyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(Trifluoromethoxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(3-(6-(2,4-Dichlorophenyl)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(2,2,2-Trifluoroethoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[3-[(1S or 1R)-2,2,2-Trifluoro-1-methyl-ethoxy]azetidin-1-yl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 10 (4aR,8aS)-6-[3-[4-[3-[(1R or 1S)-2,2,2-Trifluoro-1-methyl-ethoxy]azetidin-1-yl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(4-(2-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(4-(3-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(3-(2,2,2-trifluoroethoxy)azetidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-(3-(6-(2-(trifluoromethyl)pyrrolidin-1-yl)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(Pentafluoro-l6-sulfaneyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-(2-Fluoro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(2,2,2-Trifluoroethyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[1-(Trifluoromethyl)cyclopropyl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30


- (4aR,8aS)-6-[3-[4-(6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(5-(2,4-Dichlorophenyl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 5 (4aR,8aS)-6-(3-(4-((R or S)-2-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-((S or R)-2-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-((R or S)-3-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 10 (4aR,8aS)-6-(3-(4-((S or R)-3-(Trifluoromethyl)pyrrolidin-1-yl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-Fluoro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 15 (4aR,8aS)-6-(3-(3-Methyl-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3,5-Difluoro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(3-Chloro-4-(trifluoromethoxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-((R or S)-3-(3-Chloro-5-(2,2,2-trifluoroethoxy)phenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-((S or R)-3-(3-Chloro-5-(2,2,2-trifluoroethoxy)phenyl)pyrrolidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 25 (4aR,8aS)-6-(3-(4-(tert-Butyl)-3-methoxyphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-Propylphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(4-(Trifluoromethoxy)-3-(trifluoromethyl)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 30

- (4aR,8aS)-6-(3-(5-((R or S)-3-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
 (4aR,8aS)-6-(3-(5-((S or R)-3-(Trifluoromethyl)pyrrolidin-1-yl)pyridin-2-yl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
 5 (4aR,8aS)-6-[3-[6-[3-(R or S)-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-[6-[3-(S or R)-(trifluoromethyl)pyrrolidin-1-yl]-3-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-(4-Tetrahydropyran-3-ylphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-
 10 hexahydropyrido[4,3-b][1,4]oxazin-3-one;
 (4aR,8aS)-6-[3-[2-Methoxy-4-(2,2,2-trifluoroethyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and
 (4aR,8aS)-6-(3-(4-(Neopentyloxy)phenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one.

- 15 51. A process of manufacturing the compounds of formula (Ic) according to any one of claims 1 to 50, [or a pharmaceutically acceptable salt thereof](#), comprising:
 reacting 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (**1**),



- with a heterocyclic amine **2a**, wherein A, L, X, m, n, and R²⁰ to R²³ are as defined in
 20 any one of claims 1 to 50



in the presence of a base and a urea forming reagent,
 to form said compound of formula (Ic).

- 25 ~~52. A compound of formula (Ic) according to any one of claims 1 to 50, when manufactured according to the process of claim 51.~~

53. ~~The compound of formula (Ic) according to any one of claims 1 to 50 and 52, wherein said compound of formula (I) has an IC₅₀ for monoacylglycerol lipase below 10 μ M.~~

5 54.52. ~~_____~~ A compound of formula (Ic) according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, 52 and 53 for use as therapeutically active substance.

55.53. ~~_____~~ A pharmaceutical composition comprising a compound of formula (Ic) according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, 52 and 53 and a therapeutically inert carrier.

10 56. ~~The use of a compound of formula (Ic) according to any one of claims 1 to 50, 52 and 53 for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.~~

15 57. ~~The use of a compound of formula (Ic) according to any one of claims 1 to 50, 52 and 53 for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.~~

20 58.54. ~~_____~~ A compound of formula (Ic) according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, 52 and 53 for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

25 59.55. ~~A The~~ compound of formula (Ic) ~~according to any one of claims 1 to 50, 52 and 53~~ for use according to claim 54, wherein said neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders are selected from in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke,

epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

5 ~~60.~~ 56. ~~The use~~ Use of a compound of formula (Ic) according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, 52 and 53 for in the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

10 ~~61.~~ 57. The use of ~~a compound of formula (Ic) according to any one of claims 1 to 50, 52 and 53 for the preparation of a medicament for the treatment or prophylaxis of~~ claim 56, wherein said neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders are selected from multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy
15 induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

20 ~~62. — A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (Ic) according to any one of claims 1 to 50, 52 and 53 to the mammal.~~

25 ~~63. — A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises administering an effective amount of a compound of formula (Ic) according to any one of claims 1 to 50, 52 and 53 to the mammal.~~

~~64. — The invention as described hereinbefore.~~